Max Hodak•Co-founder, Neuralink and Founder, Science
Executive Summary
Science Corp.
has successfully treated over 40 patients with its 'Prima' retinal implant, a BCI that restores sight to the blind, and expects market approval later this year.
The company is pursuing a multi-pronged approach to neurotechnology, developing near-term electrical stimulators, mid-term optogenetic gene therapies, and long-term bio-hybrid interfaces using engineered stem cells.
Founder Max Hodak views Brain-Computer Interfaces (BCI) not as a single product but as a new category of technology, akin to pharmaceuticals, with applications ranging from medical restoration to potential consumer enhancements.
Hodak believes humanity is in a 'takeoff era' of non-incremental technological progress, where the convergence of AI and BCI will fundamentally reframe the human condition and could enable radical life extension.
8 quotes
Concerns Raised
Current high-performance BCIs require invasive brain surgery, limiting their application to severely disabled patient populations.
Neuroplasticity has limits; critical developmental periods for sensory input, if missed, can make it impossible for the brain to adapt later in life.
Advanced technologies like optogenetics still face long (5-7 year) timelines for clinical translation and regulatory approval.
Opportunities Identified
Restoring vision to millions suffering from diseases like geographic atrophy and inherited retinal diseases.
Developing a new category of BCI products, including potential non-invasive consumer applications like a 'digital Adderall' using ultrasound.
Creating bio-hybrid interfaces that could form an 'internet nerve,' directly connecting the brain to digital information.
The convergence of AI and BCI could lead to radical life extension, with the first 1,000-year-old humans potentially alive today.